ArriVent BioPharma, Inc.
AVBP
$29.79
-$0.49-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.64M | 27.19M | 24.18M | 21.08M | 19.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.94M | 156.87M | 177.53M | 162.42M | 148.33M |
| Operating Income | -175.94M | -156.87M | -177.53M | -162.42M | -148.33M |
| Income Before Tax | -163.93M | -145.44M | -166.50M | -151.17M | -136.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -163.93 | -145.44 | -166.50 | -151.17 | -136.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.93M | -145.44M | -166.50M | -151.17M | -136.98M |
| EBIT | -175.94M | -156.87M | -177.53M | -162.42M | -148.33M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.68 | -3.52 | -4.46 | -4.24 | -4.02 |
| Normalized Basic EPS | -2.29 | -2.20 | -2.79 | -2.65 | -2.51 |
| EPS Diluted | -3.68 | -3.52 | -4.46 | -4.24 | -4.02 |
| Normalized Diluted EPS | -2.29 | -2.20 | -2.79 | -2.65 | -2.51 |
| Average Basic Shares Outstanding | 177.53M | 164.93M | 153.76M | 144.53M | 136.20M |
| Average Diluted Shares Outstanding | 177.53M | 164.93M | 153.76M | 144.53M | 136.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |